Literature DB >> 16877970

Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings.

Roberto Minutolo1, Ferdinando C Sasso, Paolo Chiodini, Bruno Cianciaruso, Ornella Carbonara, Pasquale Zamboli, Giuseppina Tirino, Andrea Pota, Roberto Torella, Giuseppe Conte, Luca De Nicola.   

Abstract

OBJECTIVES: Advanced diabetic nephropathy (DN) is characterized by a marked development of cardiovascular and renal disease. These patients are frequently managed by different health professionals with the consequence that the quality of care may differ substantially. To compare the management of cardiovascular risk factors in patients with type 2 DN and an estimated glomerular filtration rate (GFR) of 15-60 ml/min per 1.73 m2 followed in nephrology, diabetology and primary care.
METHODS: This multicentre cross-sectional study verified the control of blood pressure (BP), total cholesterol, triglycerides, glycosylated haemoglobin A1c (HbA1c) and haemoglobin in patients exclusively followed in either nephrology (n = 266), diabetology (n = 246) or primary care (n = 195) of the same metropolitan area for at least 1 year.
RESULTS: Primary care patients were older and had a greater prevalence of previous cardiovascular events. The GFR was lower in nephrology than in diabetology and primary care (33 +/- 13 versus 47 +/- 9 and 40 +/- 12 ml/min per 1.73 m2, P < 0.0001). The prevalence of BP target (< 130/80 mmHg) was similarly low in nephrology, diabetology and primary care (14, 13 and 10%, P = 0.421) probably because of insufficient prescription of diuretics and low-salt diet. Whereas the prevalence of the triglycerides target was similar, that of total cholesterol (< 200 mg/dl) was larger in diabetology (63%) than in nephrology and primary care (59 and 46%, P = 0.003) because of greater statin prescription in hypercholesterolemic individuals (70, 50 and 41%, respectively, P = 0.002). The attainment of HbA1c less than 7% was less frequent in diabetology (32%) than in nephrology and primary care (61 and 46%, P = 0.0003) despite a more frequent prescription of insulin/oral agents in diabetology. The control of anaemia was better in diabetology. Multivariate analysis adjusted for the patient case-mix and physician-level clustering confirmed these differences except for anaemia.
CONCLUSION: Patients with advanced DN, despite the worst renal and cardiovascular prognosis, are at high risk of being under-treated independently of the type of clinical setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877970     DOI: 10.1097/01.hjh.0000239303.93872.31

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  27 in total

1.  Primary care management of chronic kidney disease.

Authors:  Adrienne S Allen; John P Forman; E John Orav; David W Bates; Bradley M Denker; Thomas D Sequist
Journal:  J Gen Intern Med       Date:  2010-10-05       Impact factor: 5.128

Review 2.  Biomarkers of vascular disease in diabetes: the adipose-immune system cross talk.

Authors:  Federico Biscetti; Elisabetta Nardella; Andrea Leonardo Cecchini; Andrea Flex; Raffaele Landolfi
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

3.  Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.

Authors:  Maurizio Gallieni; Nicola De Luca; Domenico Santoro; Gina Meneghel; Marco Formica; Giuseppe Grandaliano; Francesco Pizzarelli; Maria Cossu; Giuseppe Segoloni; Giuseppe Quintaliani; Salvatore Di Giulio; Antonio Pisani; Moreno Malaguti; Cosimo Marseglia; Lamberto Oldrizzi; Mario Pacilio; Giuseppe Conte; Antonio Dal Canton; Roberto Minutolo
Journal:  J Nephrol       Date:  2015-05-19       Impact factor: 3.902

4.  Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Authors:  Roberto Minutolo; Paolo Chiodini; Bruno Cianciaruso; Andrea Pota; Vincenzo Bellizzi; Deborah Avino; Sara Mascia; Simona Laurino; Valerio Bertino; Giuseppe Conte; Luca De Nicola
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

5.  Assessment for the Correlation Between Diabetic Retinopathy and Metabolic Syndrome: A Cross-Sectional Study.

Authors:  Qing Sun; Liang Tang; Qiurong Zeng; Mingjun Gu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-22       Impact factor: 3.168

6.  Impact of Isolated High Home Systolic Blood Pressure and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A 5-Year Prospective Cohort Study.

Authors:  Nobuko Kitagawa; Noriyuki Kitagawa; Emi Ushigome; Hidetaka Ushigome; Isao Yokota; Naoko Nakanishi; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Michiaki Fukui
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

7.  15-year-change of phenotype and prognosis in non-dialysis CKD patients referred to a nephrology clinic.

Authors:  Carlo Garofalo; Silvio Borrelli; Toni De Stefano; Luca De Nicola; Carlo Vita; Nicola Peruzzu; Antonella Netti; Giuseppe Conte; Michele Provenzano; Roberto Minutolo
Journal:  Int Urol Nephrol       Date:  2021-07-12       Impact factor: 2.370

Review 8.  The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.

Authors:  Teresa Salvatore; Pia Clara Pafundi; Raffaele Galiero; Gaetana Albanese; Anna Di Martino; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Ferdinando Carlo Sasso
Journal:  Front Med (Lausanne)       Date:  2021-06-30

Review 9.  Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment.

Authors:  Sameer P Leley; Thomas A Ciulla; Ashay D Bhatwadekar
Journal:  Clin Interv Aging       Date:  2021-07-15       Impact factor: 4.458

10.  Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease.

Authors:  Ferdinando Carlo Sasso; Pia Clara Pafundi; Vittorio Simeon; Luca De Nicola; Paolo Chiodini; Raffaele Galiero; Luca Rinaldi; Riccardo Nevola; Teresa Salvatore; Celestino Sardu; Raffaele Marfella; Luigi Elio Adinolfi; Roberto Minutolo
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.